A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus.
Metastasis
Nivolumab
Primary malignant melanoma of the esophagus
Recurrence
Journal
Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125
Informations de publication
Date de publication:
04 Nov 2022
04 Nov 2022
Historique:
received:
12
08
2022
accepted:
25
10
2022
entrez:
5
11
2022
pubmed:
6
11
2022
medline:
6
11
2022
Statut:
epublish
Résumé
The treatment strategy for metastatic lesions of primary malignant melanoma of the esophagus (PMME) is currently determined on a case-by-case basis, based on the National Comprehensive Cancer Network (NCCN) guidelines for cutaneous melanoma. The NCCN guidelines state that resection should be considered in patients with resectable metastatic recurrence. Herein, we report a case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for the metastatic recurrence of PMME. A 65-year-old female patient with PMME underwent thoracoscopic subtotal esophagectomy, gastric tube reconstruction via the posterior mediastinal route, and cervical esophagogastric anastomosis. Histopathological examination of the resected specimen revealed that the tumor was PMME with tumor invasion into the muscularis propria and no lymph node metastasis. At the age of 68 years, she developed intestinal invagination due to jejunal metastasis of malignant melanoma and underwent resection of the jejunum. Histopathological examination of the resected specimen revealed two metastases of malignant melanoma in the jejunum and one metastasis to the mesenteric lymph node. At the age of 75 years, a recurrence of malignant melanoma was found in the cervical esophagus. She underwent thoracoscopic mobilization of the gastric tube and esophagus followed by cervical esophagectomy and reconstruction with a free jejunum flap. She received 24 courses of nivolumab therapy for 1 year as a postoperative adjuvant therapy. Subsequently, at the age of 78 years, an enlarged left cervical lymph node and a mass in the right lower lobe of the lung were found. She underwent left cervical lymph node dissection and thoracoscopic wedge resection of the right lung. Histopathological examination of the resected specimens revealed that both tumors were metastases of malignant melanoma. At age 79 years, she received eight courses of nivolumab therapy as a second postoperative adjuvant therapy, with no sign of recurrence in a 9-month follow-up period after the third metastasectomy. In cases of metastatic recurrence of PMME, aggressive resection of oligometastasis with postoperative adjuvant nivolumab therapy may result in long-term survival.
Sections du résumé
BACKGROUND
BACKGROUND
The treatment strategy for metastatic lesions of primary malignant melanoma of the esophagus (PMME) is currently determined on a case-by-case basis, based on the National Comprehensive Cancer Network (NCCN) guidelines for cutaneous melanoma. The NCCN guidelines state that resection should be considered in patients with resectable metastatic recurrence. Herein, we report a case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for the metastatic recurrence of PMME.
CASE PRESENTATION
METHODS
A 65-year-old female patient with PMME underwent thoracoscopic subtotal esophagectomy, gastric tube reconstruction via the posterior mediastinal route, and cervical esophagogastric anastomosis. Histopathological examination of the resected specimen revealed that the tumor was PMME with tumor invasion into the muscularis propria and no lymph node metastasis. At the age of 68 years, she developed intestinal invagination due to jejunal metastasis of malignant melanoma and underwent resection of the jejunum. Histopathological examination of the resected specimen revealed two metastases of malignant melanoma in the jejunum and one metastasis to the mesenteric lymph node. At the age of 75 years, a recurrence of malignant melanoma was found in the cervical esophagus. She underwent thoracoscopic mobilization of the gastric tube and esophagus followed by cervical esophagectomy and reconstruction with a free jejunum flap. She received 24 courses of nivolumab therapy for 1 year as a postoperative adjuvant therapy. Subsequently, at the age of 78 years, an enlarged left cervical lymph node and a mass in the right lower lobe of the lung were found. She underwent left cervical lymph node dissection and thoracoscopic wedge resection of the right lung. Histopathological examination of the resected specimens revealed that both tumors were metastases of malignant melanoma. At age 79 years, she received eight courses of nivolumab therapy as a second postoperative adjuvant therapy, with no sign of recurrence in a 9-month follow-up period after the third metastasectomy.
CONCLUSION
CONCLUSIONS
In cases of metastatic recurrence of PMME, aggressive resection of oligometastasis with postoperative adjuvant nivolumab therapy may result in long-term survival.
Identifiants
pubmed: 36333558
doi: 10.1186/s40792-022-01561-z
pii: 10.1186/s40792-022-01561-z
pmc: PMC9636353
doi:
Types de publication
Journal Article
Langues
eng
Pagination
206Informations de copyright
© 2022. The Author(s).
Références
J Surg Res. 2021 Apr;260:46-55
pubmed: 33316759
Lancet Oncol. 2016 Sep;17(9):1283-94
pubmed: 27451390
Jpn J Clin Oncol. 2007 Feb;37(2):140-5
pubmed: 17255158
Thorac Cancer. 2019 Apr;10(4):950-956
pubmed: 30864295
J Thorac Oncol. 2009 Sep;4(9):1180-2
pubmed: 19704341
J Clin Oncol. 2017 Jan 10;35(2):226-235
pubmed: 28056206
Lancet Oncol. 2020 Nov;21(11):1465-1477
pubmed: 32961119
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
N Engl J Med. 2021 Jun 3;384(22):2102-2114
pubmed: 34077643
N Engl J Med. 2021 Apr 1;384(13):1191-1203
pubmed: 33789008
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Int J Clin Oncol. 2005 Jun;10(3):204-7
pubmed: 15990972
Int J Clin Oncol. 2020 Nov;25(11):1951-1959
pubmed: 32740718
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
Lancet. 2021 Jan 30;397(10272):375-386
pubmed: 33485464
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Eur J Cancer. 2020 Oct;138:11-18
pubmed: 32829104
Cancer Chemother Pharmacol. 2017 Nov;80(5):999-1004
pubmed: 28983657
J Med Case Rep. 2021 May 5;15(1):237
pubmed: 33947459
Int J Surg Case Rep. 2020;75:152-156
pubmed: 32950945
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
N Engl J Med. 2022 Feb 3;386(5):449-462
pubmed: 35108470
Lancet Oncol. 2019 Nov;20(11):1506-1517
pubmed: 31582355
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Mol Clin Oncol. 2018 Apr;8(4):528-532
pubmed: 29541462
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Int J Clin Oncol. 2020 May;25(5):972-977
pubmed: 31938955
J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402
pubmed: 30959471
Thorac Cancer. 2013 Nov;4(4):479-483
pubmed: 28920227
J Thorac Cardiovasc Surg. 2020 Mar 20;:
pubmed: 32359897